Literature DB >> 33276428

Potential Roles of Tumor Cell- and Stroma Cell-Derived Small Extracellular Vesicles in Promoting a Pro-Angiogenic Tumor Microenvironment.

Nils Ludwig1, Dominique S Rubenich2, Łukasz Zaręba3, Jacek Siewiera4, Josquin Pieper5, Elizandra Braganhol2, Torsten E Reichert1, Mirosław J Szczepański3.   

Abstract

Extracellular vesicles (EVs) are produced and released by all cells and are present in all body fluids. They exist in a variety of sizes, however, small extracellular vesicles (sEVs), the EV subset with a size range from 30 to 150 nm, are of current interest. They are characterized by a distinct biogenesis and complex cargo composition, which reflects the cytosolic contents and cell-surface molecules of the parent cells. This cargo consists of proteins, nucleic acids, and lipids and is competent in inducing signaling cascades in recipient cells after surface interactions or in initiating the generation of a functional protein by delivering nucleic acids. Based on these characteristics, sEVs are now considered as important mediators of intercellular communication. One hallmark of sEVs is the promotion of angiogenesis. It was shown that sEVs interact with endothelial cells (ECs) and promote an angiogenic phenotype, ultimately leading to increased vascularization of solid tumors and disease progression. It was also shown that sEVs reprogram cells in the tumor microenvironment (TME) and act in a functionally cooperative fashion to promote angiogenesis by a paracrine mechanism involving the differential expression and secretion of angiogenic factors from other cell types. In this review, we will focus on the distinct functions of tumor-cell-derived sEVs (TEX) in promotion of angiogenesis and describe their potential as a therapeutic target for anti-angiogenic therapies. Also, we will focus on non-cancer stroma-cell-derived small extracellular vesicles and their potential role in stimulating a pro-angiogenic TME.

Entities:  

Keywords:  angiogenesis; cancer; small extracellular vesicles; tumor microenvironment; tumor-derived exosomes

Year:  2020        PMID: 33276428     DOI: 10.3390/cancers12123599

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  7 in total

Review 1.  Targeting tumor-associated macrophages for cancer treatment.

Authors:  Mengjun Li; Linye He; Jing Zhu; Peng Zhang; Shufang Liang
Journal:  Cell Biosci       Date:  2022-06-07       Impact factor: 9.584

2.  Small Extracellular Vesicles from Head and Neck Squamous Cell Carcinoma Cells Carry a Proteomic Signature for Tumor Hypoxia.

Authors:  Alicja Głuszko; Mirosław J Szczepański; Theresa L Whiteside; Torsten E Reichert; Jacek Siewiera; Nils Ludwig
Journal:  Cancers (Basel)       Date:  2021-08-19       Impact factor: 6.639

3.  Predictive Role of Tumor-Stroma Ratio for Survival of Patients With Non-Small Cell Lung Cancer: A Meta-Analysis.

Authors:  Xuefeng Zhang; Hongfu Ma; Liang Zhang; Fenghuan Li
Journal:  Pathol Oncol Res       Date:  2022-01-21       Impact factor: 3.201

Review 4.  The Role of Tumor-Derived Exosomes (TEX) in Shaping Anti-Tumor Immune Competence.

Authors:  Theresa L Whiteside
Journal:  Cells       Date:  2021-11-06       Impact factor: 6.600

Review 5.  Differences of Angiogenesis Factors in Tumor and Diabetes Mellitus.

Authors:  Shidong Tan; Guangyao Zang; Ying Wang; Zhen Sun; Yalan Li; Cheng Lu; Zhongqun Wang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-24       Impact factor: 3.168

Review 6.  Cancer Stem Cells and Their Vesicles, Together with Other Stem and Non-Stem Cells, Govern Critical Cancer Processes: Perspectives for Medical Development.

Authors:  Jacopo Meldolesi
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

7.  Breast cancer cell-derived extracellular vesicles transfer miR-182-5p and promote breast carcinogenesis via the CMTM7/EGFR/AKT axis.

Authors:  Chong Lu; Yu Zhao; Jing Wang; Wei Shi; Fang Dong; Yue Xin; Xiangwang Zhao; Chunping Liu
Journal:  Mol Med       Date:  2021-07-16       Impact factor: 6.354

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.